Dennemeyer Octimine

Aids patents

Laura HorcajadaLaura Horcajada

Peptides involved in the pathogenesis of hiv infection

Peptides involved in the pathogenesis of human immunodeficiency virus (''HIV''). More particularly, this invention relates to peptides from the env region of the HIV genome and the use of such peptides in methods and compositions for preventing, treating, or detecting acquired immune deficiency syndrome (''AIDS'') infection.

Publication number: EP0269712A4 | Search similar patents

Assays for detecting substances with an anti-hiv action

The invention relates to new assays for detecting substances influencing apoptosis for a new treatment of the disease caused by the human immunodeficiency virus (HIV). The invention is based on the discovery in the human immunodeficiency virus (HIV) of a new region homologous to the 'death effector domain' (DED) and on a new antiviral strategy, based on said discovery, for eliminating HIV-infected cells from the body and preventing the acquired immune deficiency syndrome (AIDS).

Publication number: WO9947696A2 | Search similar patents

Method of inhibiting hiv infection with cd44 and anti-cd44 antibodies

The present invention relates to a method of inhibiting HIV infection of cells susceptible to HIV infection. The method comprises contacting such cells with an agent (such as an anti-CD44 antibody) that inhibits CD44-facilitated HIV infection of the cells.

Publication number: US6432405B1 | Search similar patents

Cure for the human immunodeficiency virus

A method whereby a cure is found for the Human Immunodeficiency Virus (HIV) by rebuilding and stimulating the infected individual's immune system.

Publication number: US2009081176A1 | Search similar patents

Method for detecting hiv-1 and kit to be used for the method

A method for detecting HIV-1 reliably that can be used for the diagnosis of HIV-1 infection simply and reliably and a kit to be used for the method are provided. The method for detecting HIV-1 in human serum, a human serum-derived blood preparation or serum for transfusion by an ELISA method characterized by using an antibody (anti-HIV-1 p24 antibody) that recognizes and binds to p24 antigen (HIV-1 p24) that is expressed in human immunodeficiency virus (HIV-1) in the growth phase, the method for detecting human-derived p24 antibody in the serum and an ELISA kit for detecting HIV-1 p24 antigen/antibody to be used for the method are provided.

Publication number: WO2006126287A1 | Search similar patents

Method and device for predicting hiv infection development time in postpartum women


The invention relates to the field of medicine. The present method for predicting the postpartum critical development time of HIV infection consists in measuring the viral load count in a pregnant HIV-infected woman at the 12th week of pregnancy, prior to commencement of therapy to induce immune control of HIV, and determining the age of the woman and the duration of the disease in terms of number of full years plus number of full months divided by twelve. At the 30th week of pregnancy, against the background of the above-mentioned therapy, the number of CD4+-T lymphocytes is measured and a time count for the critical development of HIV infection postpartum is calculated using a specific formula. A prediction device comprises a base in the form of a disc marked with two concentric scales, one of which corresponds to outcome counts, and the other of which corresponds to a factor affecting these counts. Furthermore, four discs of smaller diameter are rotatably mounted coaxially with the base, said discs being marked with scales for other factors affecting the outcome counts. The diameter of each successive disc is smaller than the diameter of the preceding disc. Each disc is provided with a pointer in the form of a protrusion. The disc having the smallest diameter is not marked with a scale and is provided with two pointers, one of which is long enough to interact with the outcome count scale.

Publication number: WO2015133935A1 | Search similar patents

Use of a polypeptide having soluble human cd16 activity for treating hiv infection

The use of a polypeptide having soluble human CD16 activity for preparing a pharmaceutical composition for preventing or reducing HIV infection in humans is disclosed.

Publication number: WO9713524A1 | Search similar patents

Disease management system

A comprehensive disease management system providing advanced diagnostic, prognostic and therapeutic capabilities to healthcare workers located in remote, rural and resource-poor urban centers is disclosed. Additionally, a method of managing disease in a patient located remotely relative to interpretation and therapeutic dispensing services is provided including methods of data collection, data interpretation and therapeutic dispensing. An algorithm is disclosed to provide non-physician healthcare workers in remote, rural and resource-poor urban centers to manage disease in patients with human immunodeficiency virus (HIV) disease.

Publication number: EP1706837A2 | Search similar patents

Method for detecting hiv-1 without being affected by anti-mouse protein antibody existing in human and kit to be used for the same

A method for detecting HIV-1 reliably that can be used for the diagnosis of HIV-1 infection simply and reliably and a kit to be used for the same are provided. The method for detecting HIV-1 in human serum, a human serum-derived blood preparation or serum for transfusion by an ELISA method characterized by using an antibody (anti-HIV-1 p24 antibody) that recognizes and binds to p24 antigen (HIV-1 p24) that is expressed in human immunodeficiency virus (HIV-1) in the growth phase without being affected by an anti-mouse protein antibody existing in human blood, a method for detecting a human-derived p24 antibody in the serum and an ELISA kit for detecting HIV-1 p24 antigen/antibody to be used for the method are provided.

Publication number: WO2008059553A1 | Search similar patents

Methods of preventing and treating hiv infection

The present invention relates, in general, to a method of preventing or treating human immunodeficiency virus (HIV) infection, and in particular, to a method of preventing or treating HIV infection using a cobalamin. The invention further relates to compositions suitable for use in such a method.

Publication number: US6787527B1 | Search similar patents

System for controlling the spread of hiv/aids and other infectious

A method for controlling the spread of HIV/AIDS and other infectious diseases. Individuals desirous of reducing the risks of infection and preventing the spread of such diseases voluntarily participate in a testing program whereby regular periodic screening tests are performed to indicate the infection status of each such individual for any of several infectious diseases. The infection status information is coded for each individual and is stored in a confidential database. An individual can access his infection status information upon making an inquiry using a unique personal identification number, or PIN. The individual's identification information is matched with his infection status information in the database and provides that information immediately either orally or in written form. Two participating members of the program can obtain their infection status data jointly, thereby providing reliable, current infection status information to each other contemporaneously while avoiding the risks of nondisclosure or misrepresentation of such information by one or both parties.

Publication number: EP0844850A1 | Search similar patents

Skin test and test kit for aids

A method for the detection of AIDS virus infection in humans involves the introduction of an effective amount of an immunogenic AIDS virus envelope protein intradermally into a human and the subsequent observation of the injection site for an immune response, such as a characteristic redness or swelling.

Publication number: EP0370573A3 | Search similar patents

Utilization of molecules recognized by auto-antibodies of human serums for the diagnosis or treatment of aids

The invention relates to the utilization of one or a plurality of molecules capable of being recognized by auto-antibodies present in the serum of patients infected by the HIV type virus, and to the implementation of methods of diagnosis in vitro of the infection of a person by the HIV type virus, or the preparation of medicaments intended for the treatment of AIDS.

Publication number: WO9427151A1 | Search similar patents

Method for detection of human immunodeficiency virus and cell lines useful therefor

A method provided for assaying for human immunodeficiency virus comprises: seeding dishes with cells susceptible to HIV infection; adding to the dishes a sample to be tested for HIV infection; incubating the cells; exposing the cells to a first antibody reactive with HIV proteins; exposing the cells to marker-conjugated antibody reactive with the first antibody; examining the dishes with a suitable microscope; and counting the number of foci of marker-positive cells per dish to determine the number of infected cells in the dish. The process can be used to detect and to quantify HIV-infected cells, which permits monitoring of the effects of drug therapy on the levels of HIV expression in AIDS patients, as well as providing a quantitative measure of HIV expression in asymptomatic HIV antibody-positive individuals.

Publication number: EP0514494A1 | Search similar patents

Game of the immune system

The present invention provides a board game for use as a didactic teaching-aid for individuals that are interested in the immune system. The game comprises a playing board having a continuous main course having a plurality of playing spaces. Each playing space contains a number that matches the number of an immune scenario vignette that constitutes an exposure to an infectious disease or to an immune disease state, such as an auto-immune disease or an immune-deficiency. A method of curing or treating the disease, and information about the disease is provided in a disease handout that the players reference while tending to their disease at a hospital, clinic or pharmacy, depending on the nature of the exposure. When a player attains immunity, they become immune to those diseases that are subsequently encountered.

Publication number: US5556100A | Search similar patents

Start your free patent search now.

+49 89 444 78663 0 | contact@octimine.com | © octimine technologies GmbH, 2017